Page last updated: 2024-10-24

carmustine and Lymphoma

carmustine has been researched along with Lymphoma in 169 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.

Research Excerpts

ExcerptRelevanceReference
" In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018."9.30Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. ( Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J, 2019)
"Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/fludarabine/total body irradiation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study."9.17Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. ( Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M, 2013)
"We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n = 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m(2) (eBEAM; n = 64 from May 1995 to June 1999)."9.11Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. ( Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA, 2004)
"To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients with non-AIDS-related primary CNS lymphoma (PCNSL) treated in a multicenter setting."9.10High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. ( Fickers, M; Haaxma-Reiche, H; Hansen, M; Kluin-Nelemans, HC; Poortmans, PM; Rozewicz, C; Soubeyran, P; Taphoorn, M; Teodorovic, I; Thomas, J; Van den Bent, M; van Glabbeke, M; Van Imhoff, G; Van't Veer, M, 2003)
"We performed a phase II study to determine the efficacy of maximal cytoreductive therapy with up to five cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU], etoposide, cytarabine, and melphalan) followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for patients with advanced relapsed or refractory indolent lymphoma."9.09Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma. ( Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J, 2000)
" Thirty seven patients with refractory lymphoma received 400 mg/m2/day of etoposide, and 13 patients 600 mg/m2/day, in addition to BCNU, cytarabine, and melphalan."9.08Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. ( Goldstone, AH; Linch, DC; Mills, W; Strang, J, 1995)
"Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT."9.07High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. ( Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, HM; Shina, DC; Topolsky, D, 1992)
"We conducted a dose-finding study of mitoxantrone (MITO) in combination with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT)."9.07Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ( Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D, 1994)
"We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma."9.07Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994)
"Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months."9.04BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977)
"Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse."7.83Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. ( Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E, 2016)
"Single-dose palonosetron was more effective than ondansetron treatment to prevent acute and delayed nausea and vomiting following HDC before HSCT."7.75Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009)
"Thirty adults with primary refractory or recurrent intermediate- or low-grade lymphoma were treated on a prospective phase II study with carmustine 300 mg/m2 i."7.70Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. ( Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K, 1999)
"We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma."7.69A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. ( Smith, RJ; Sweetenham, JW, 1995)
"One hundred forty-three patients with cutaneous T cell lymphoma were treated with topical carmustine (BCNU)."7.68Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. ( Crain, WR; Epstein, EH; Zackheim, HS, 1990)
"Eighteen patients with high-grade malignant lymphoma were treated with ifosfamide-VP16213 combinations after failing to respond completely or after relapsing on CHOP-like therapy."7.67Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma. ( Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ, 1988)
"Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses."7.651,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975)
"SUMMARY-A model has been derived for the effect of the chemotherapeutic agents cyclophosphamide (CY), 5-fluorouracil (5-FU), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on the survival of mice bearing a transplantable lymphoma."7.64Survival of mice bearing a transplanted syngeneic lymphoma following treatment with cyclophosphamide, 5-fluorouracil, or 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Bruce, WR; Meeker, BE; Valeriote, FA, 1967)
"The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years."6.82Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016)
"Lymphoma is seen as a highly treatable and curable malignancy with aggressive treatment methods."5.72Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma. ( Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I, 2022)
" We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT."5.42High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. ( Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015)
"A total of 123 patients with lymphoma receiving the BEAM (carmustine, etoposide, aracytin, and melphalan) conditioning regimen had a significant 5% drop in mean forced vital capacity and total lung capacity but no significant change in forced expiratory volume in one second/forced vital capacity ratio nor in diffusion lung capacity of carbon monoxide adjusted to volume."5.34Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience. ( Bazarbachi, A; Bou Akl, I; El-Cheikh, J; Ghaoui, N; Karout, L; Khalil, PB; Massoud, R; Matar, M; Zahreddine, A, 2020)
" In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018."5.30Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. ( Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J, 2019)
"Bacteremia was documented in two patients in the O+R group and six in the control group (p=0."5.30Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. ( Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A, 1999)
"Twenty-four patients autografted for malignant lymphoma have been followed."5.29Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas. ( Carlson, K; Hagberg, H; Oberg, G; Simonsson, B; Smedmyr, B, 1993)
"Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1."5.29High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. ( Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S, 1993)
"Levamisole (LMS) has been considered an immunorestorative agent capable of enhancing host's antitumor immune responses."5.28Role of levamisole as immunomodulant in mouse lymphoma model. ( Bulgarini, B; De Vecchis, L; Giuliani, A; Turriziani, M, 1991)
"Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/fludarabine/total body irradiation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study."5.17Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. ( Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M, 2013)
"With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation."5.15A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. ( Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH, 2011)
"We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n = 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m(2) (eBEAM; n = 64 from May 1995 to June 1999)."5.11Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. ( Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA, 2004)
"To assess the effect of a reduced dose of radiotherapy (RT) in patients with primary CNS lymphoma (PCNSL) responding to the cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/carmustine, vincristine, methotrexate, and cytarabine (BVAM) regimen."5.10Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. ( Bessell, EM; Byrne, P; Graus, F; López-Guillermo, A; Montserrat, E; Nomdedeu, B; Petit, J; Verger, E; Villá, S, 2002)
"To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients with non-AIDS-related primary CNS lymphoma (PCNSL) treated in a multicenter setting."5.10High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. ( Fickers, M; Haaxma-Reiche, H; Hansen, M; Kluin-Nelemans, HC; Poortmans, PM; Rozewicz, C; Soubeyran, P; Taphoorn, M; Teodorovic, I; Thomas, J; Van den Bent, M; van Glabbeke, M; Van Imhoff, G; Van't Veer, M, 2003)
"We performed a phase II study to determine the efficacy of maximal cytoreductive therapy with up to five cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU], etoposide, cytarabine, and melphalan) followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for patients with advanced relapsed or refractory indolent lymphoma."5.09Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma. ( Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J, 2000)
" Thirty seven patients with refractory lymphoma received 400 mg/m2/day of etoposide, and 13 patients 600 mg/m2/day, in addition to BCNU, cytarabine, and melphalan."5.08Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. ( Goldstone, AH; Linch, DC; Mills, W; Strang, J, 1995)
"We conducted a dose-finding study of mitoxantrone (MITO) in combination with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT)."5.07Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ( Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D, 1994)
"We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma."5.07Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994)
"Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT."5.07High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. ( Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, HM; Shina, DC; Topolsky, D, 1992)
"A total of 296 evaluable patients with unfavorable categories of malignant lymphoma were randomly assigned treatment with cyclophosphamide, vincristine, and prednisone plus BCNU (BCOP) or doxorubicin (CHOP)."5.05Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. ( Bartolucci, AA; Dandy, M; Gams, RA; Omura, G; Rainey, M; Silberman, H, 1985)
"Fifty-two patients with stage III or IV nodular mixed lymphocytic-histiocytic lymphoma (NM) were entered on a prospective randomized trial comparing cyclophosphamide-prednisone (CP) to either COPP (cyclophosphamide, vincristine, procarbazine, prednisone) or BCVP (BCNU, cyclophosphamide, vincristine, prednisone)."5.05Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. ( Barnes, JM; Bennett, JM; Berard, CW; Ezdinli, EZ; Glick, JH; Orlow, EL, 1981)
"Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months."5.04BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977)
"Based on experience with comprehensive patient involvement, we present data from implementation of portable, programmable infusion pumps (PPP) for home-based chemotherapy administration in patients with acute leukaemia and in lymphoma patients receiving (carmustine, etoposide, cytarabine, melphalan) BEAM regimen."3.88Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma. ( Dünweber, A; Fridthjof, KS; Friis, LS; Gørløv, JS; Kampmann, P; Kjeldsen, L; Moser, C; Møller, T; Nexø, C; Nørskov, KH; Welinder, PC, 2018)
"Autologous stem cell transplantation (ASCT) following BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning is standard of care in relapsed low- and high-grade B-cell lymphoma (DLBCL) and other lymphoproliferative disorders, but BCNU is associated with interstitial pneumonia and an increased mortality."3.88High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. ( Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R, 2018)
"BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas."3.88A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. ( Billio, A; Borghero, C; Calimeri, T; Carli, G; Cascavilla, N; Centurioni, R; Chiusolo, P; Codeluppi, K; Fama, A; Fanin, R; Federici, I; Ferrero, S; Finotto, S; Gherlinzoni, F; Ghione, P; Giannoccaro, M; Lanza, F; Loseto, G; Marino, D; Matera, R; Mazzone, AM; Mosna, F; Olivieri, A; Olivieri, J; Orciuolo, E; Pelosini, M; Perali, G; Rattotti, S; Saraceni, F; Sgherza, N; Sica, S; Stefani, PM; Tisi, MC; Tomei, G; Zaja, F, 2018)
"Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse."3.83Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. ( Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E, 2016)
"High-dose BEAM chemotherapy (BCNU, etoposide, Ara-C, and melphalan) followed by autologous hematopoietic stem cell transplantation is frequently used as consolidative therapy for patients with recurrent or refractory Hodgkin or non-Hodgkin lymphoma."3.83Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. ( Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L, 2016)
" Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) on days 2 through 5 (total 6 g/m(2)), and etoposide 700 mg/m(2) per day on days 2 through 4 (total 2,100 mg/m(2))."3.81Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. ( Ford, PA; Grant, SJ; Keck, G; Mick, R, 2015)
"Single-dose palonosetron was more effective than ondansetron treatment to prevent acute and delayed nausea and vomiting following HDC before HSCT."3.75Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009)
"In the histiocytic lymphomas, BCNU added to CVP increases the percentage of CRs but it does so at the expense of considerable toxicity."3.74Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. ( Bennett, JM; Carbone, PP; Ezdinli, E; Johnson, GJ; Lenhard, RE; Pocock, SJ, 1977)
"Between January 1996 and July 2002, 72 patients with non-Hodgkin's lymphoma or Hodgkin's disease underwent high-dose chemotherapy with autologous stem cell transplant conditioned with either cyclophosphamide, etoposide, carmustine (CEB) or carmustine, etoposide, cytarabine, melphalan (BEAM) at a single institution."3.72High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. ( Ball, ED; Bashey, A; Carrier, E; Chen, YA; Corringham, S; Holman, P; Wang, EH, 2004)
"Thirty adults with primary refractory or recurrent intermediate- or low-grade lymphoma were treated on a prospective phase II study with carmustine 300 mg/m2 i."3.70Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. ( Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K, 1999)
" In an attempt to reduce the high procedure-related mortality reported with allografting in lymphoma, we have used BEAM (BCNU, etoposide, cytarabine and melphalan), a standard conditioning regimen for autologous transplantation."3.70Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. ( Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H, 2000)
"We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma."3.69A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. ( Smith, RJ; Sweetenham, JW, 1995)
"The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma."3.68Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. ( Dreger, P; Eckstein, V; Haferlach, T; Jacobs, S; Löffler, H; Marquardt, P; Müller-Ruchholtz, W; Mülverstedt, T; Schmitz, N; Suttorp, M, 1993)
"One hundred forty-three patients with cutaneous T cell lymphoma were treated with topical carmustine (BCNU)."3.68Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. ( Crain, WR; Epstein, EH; Zackheim, HS, 1990)
"Sixteen children with non-Hodgkin's lymphoma (NHL) who had relapsed were treated with high-dose chemotherapy with BCNU, cyclophosphamide, cytarabine, 6-thioguanine (high-dose chemotherapy [HDC]) and autologous bone marrow transplantation (ABMT)."3.67High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. ( Beaujean, F; Hartmann, O; Kalifa, C; Lemerle, J; Parmentier, C; Patte, C; Pein, F, 1984)
"58 consecutively referred, previously untreated patients with nodular lymphomas (stages III and IV) were treated with two different combination chemotherapy regimens-(cyclophosphamide, vincristine and prednisone (COP), and BCNU , cyclophosphamide, vincristine, melphalan and prednisone (M-2) - to compare remission induction and duration as well as survival."3.67Comparison of M-2 protocol with COP in patients with nodular lymphoma. ( Case, DC, 1984)
"From 1981 to 1983, 208 patients with recurrent or refractory lymphoma were treated with methylglyoxal-bis-guanylhydrazone (methyl-GAG), ifosfamide, methotrexate, etoposide (MIME)."3.67Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; Jagannath, S; McLaughlin, P; Redman, JR; Rodriguez, MA; Swan, F; Velasquez, WS, 1988)
"Eighteen patients with high-grade malignant lymphoma were treated with ifosfamide-VP16213 combinations after failing to respond completely or after relapsing on CHOP-like therapy."3.67Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma. ( Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ, 1988)
"Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses."3.651,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975)
"SUMMARY-A model has been derived for the effect of the chemotherapeutic agents cyclophosphamide (CY), 5-fluorouracil (5-FU), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on the survival of mice bearing a transplantable lymphoma."3.64Survival of mice bearing a transplanted syngeneic lymphoma following treatment with cyclophosphamide, 5-fluorouracil, or 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Bruce, WR; Meeker, BE; Valeriote, FA, 1967)
"The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years."2.82Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016)
"Forty-five malignant lymphoma patients (mean age 38 years, M:F 30:15), undergoing the highly emetogenic regimen BEAM prior to ASCT, were randomized to receive IV granisetron (G) 3 mg once a day, IV tropisetron (T) 5 mg once a day, or IV ondansetron (0) 8 mg twice daily, for six days."2.69Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. ( Klener, P; Procházka, B; Slabý, J; Trnený, M, 2000)
" In summary, the DexaBEAM/G-CSF/CBV strategy appears to be safe and effective for salvage treatment in patients with poor risk malignant lymphomas."2.68Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. ( Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E, 1996)
"Fifty-six patients with non-Hodgkin's lymphoma (NHL, n = 26), Hodgkin's disease (HD, n = 17), or acute lymphoblastic leukemia (ALL, n = 13) with a history of previous radiation therapy were treated with cyclophosphamide (7."2.68High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. ( Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH, 1995)
"Radiation therapy for five primary brain tumors is discussed based on the results of prospective trials."2.42[Evidence-based radiation therapy for primary brain tumors]. ( Kono, T; Nankoh, S; Shibamoto, Y; Taniguchi, H; Tomita, N; Tsuji, H, 2003)
"Lymphoma is seen as a highly treatable and curable malignancy with aggressive treatment methods."1.72Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma. ( Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I, 2022)
" We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT."1.42High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. ( Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015)
"Pneumonitis is a complication of high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) regimens containing BCNU."1.38Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. ( Abramson, JS; Armand, P; Brown, JR; Chen, YB; Feng, Y; Fisher, DC; Freedman, AS; Jacobsen, ED; LaCasce, AS; Lane, AA; McAfee, SL; Neuberg, DS; Spitzer, TR, 2012)
"In heavily pretreated lymphoma patients in whom poor PBPC mobilization is expected, BMT may represent an attractive option."1.33Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma. ( Caballero, MD; del Cañizo, MC; López-Holgado, N; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L, 2005)
"Mini-BEAM/HSC is an effective treatment for lymphoma relapses after allogeneic HSCT, but optimal strategies of remission consolidation and prevention of treatment-related complications are needed to improve outcome."1.32Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor. ( Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL, 2003)
"Bacteremia was documented in two patients in the O+R group and six in the control group (p=0."1.30Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. ( Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A, 1999)
"Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1."1.29High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. ( Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S, 1993)
"Twenty-four patients autografted for malignant lymphoma have been followed."1.29Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas. ( Carlson, K; Hagberg, H; Oberg, G; Simonsson, B; Smedmyr, B, 1993)
"Levamisole (LMS) has been considered an immunorestorative agent capable of enhancing host's antitumor immune responses."1.28Role of levamisole as immunomodulant in mouse lymphoma model. ( Bulgarini, B; De Vecchis, L; Giuliani, A; Turriziani, M, 1991)
"The glutathione inhibitor drugs, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and buthionine sulfoximine (BSO), were tested in vitro in order to assess their cytotoxic effectiveness when combined with an enzyme immunotoxin (eIT) composed of a T-cell reactive monoclonal antibody (mAb) 097 coupled to the reactive oxygen-generating enzyme, glucose oxidase (GO) (EC 1."1.28Enhanced in vitro cytotoxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea or buthionine sulfoximine combined with a reactive oxygen-generating enzyme immunotoxin. ( Beaujean, F; Goavec, M; Ito, H; Morizet, J; Rousseau, V; Stanislawski, M, 1990)
" Estrogen replacement should be initiated after transplantation in women to prevent adverse effects of long-term ovarian failure."1.28Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. ( Bauer, H; Fehrentz, D; Hunstein, W; Keilholz, U; Körbling, M, 1989)
" bolus pharmacokinetic data."1.28Pharmacokinetics of very high-dose oral melphalan in cancer patients. ( Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE, 1990)
"Twenty-one patients had malignant lymphomas, three, acute lymphoblastic leukemia (ALL), and two, malignant thymomas."1.27Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. ( Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ, 1988)
"In 11 patients with non-Hodgkin's lymphoma (NHL) there were 2 complete remissions (CRs) and 2 partial remissions (PRs), and in 6 patients with Hodgkin's disease there were 5 CRs."1.27Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. ( Anderson, CC; Cawley, JC; Goldstone, AH; Harper, PG; Jelliffe, AM; Jones, M; Linch, DC; Machin, SJ; McLennan, KA; Souhami, RL, 1986)
"Ten patients developed pulmonary fibrosis after bischloroethylnitrosourea (BCNU) therapy for malignancy."1.26Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). ( Bartolucci, AA; Durant, JR; Langford, KH; Murad, TM; Norgard, MJ, 1979)
" The three drugs show similar threshold-type dose-response survival curves on asynchronous cells treated for 1 hr."1.26A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells. ( Drewinko, B; Gottlieb, JA; Loo, TL, 1976)

Research

Studies (169)

TimeframeStudies, this research(%)All Research%
pre-199070 (41.42)18.7374
1990's41 (24.26)18.2507
2000's24 (14.20)29.6817
2010's23 (13.61)24.3611
2020's11 (6.51)2.80

Authors

AuthorsStudies
Schenone, L1
Houillier, C1
Tanguy, ML1
Choquet, S2
Agbetiafa, K1
Ghesquières, H1
Damaj, G2
Schmitt, A1
Bouabdallah, K1
Ahle, G1
Gressin, R1
Cornillon, J1
Houot, R1
Marolleau, JP1
Fornecker, LM1
Chinot, O1
Peyrade, F2
Bouabdallah, R2
Moluçon-Chabrot, C1
Gyan, E1
Chauchet, A1
Casasnovas, O1
Oberic, L1
Delwail, V2
Abraham, J1
Roland, V1
Waultier-Rascalou, A1
Willems, L1
Morschhauser, F1
Fabbro, M1
Ursu, R1
Thieblemont, C1
Jardin, F1
Tempescul, A1
Malaise, D1
Touitou, V1
Nichelli, L1
Le Garff-Tavernier, M1
Plessier, A1
Bourget, P1
Bonmati, C1
Wantz-Mézières, S1
Giordan, Q1
Dorvaux, V1
Charron, C1
Jabeur, W1
Hoang-Xuan, K1
Taillandier, L1
Soussain, C1
Lachance, S1
Bourguignon, A1
Boisjoly, JA1
Bouchard, P1
Ahmad, I1
Bambace, N1
Bernard, L1
Cohen, S1
Delisle, JS1
Fleury, I1
Kiss, T1
Mollica, L1
Roy, DC1
Sauvageau, G1
Veilleux, O1
Zehr, J1
Chagnon, M1
Roy, J1
Cohen, YI1
Lebel, E1
Zimran, E1
Shaulov, A1
Stepensky, P1
Grisariu, S1
Avni, B1
Ahern, K1
Pham, J1
Sanderson, R1
Correia De Farias, M1
Walsh, K1
Bou Akl, I1
Matar, M1
Khalil, PB1
Massoud, R1
Ghaoui, N1
Karout, L1
Zahreddine, A1
Bazarbachi, A1
El-Cheikh, J1
Choi, JY1
Kang, HJ1
An, HY1
Hong, KT1
Shin, HY1
Marchesi, F1
Capria, S1
Pedata, M1
Terrenato, I1
Ballotta, L1
Riccardi, C2
Papa, E1
Riemma, C1
Trisolini, S1
Celentano, M1
Regazzo, G1
Ferrara, F2
Mengarelli, A1
Picardi, A1
Kelsey, P1
Pearce, R1
Perry, J1
Kirkland, K1
Paul, R1
Lambert, J2
Peniket, A2
Malladi, R1
Snowden, JA1
Morley, N1
AlJohani, NI1
Nasani, M1
Ahmed, HE1
Ur Rehman, J1
Nawaz, A1
Alzahrani, Z1
Albeirouti, B1
Gunes, AK1
Serin, I1
Demir, I1
Sarifakiogullari, S1
Durusoy, SS1
Akkurt, DM1
Ince, I1
Ozkan, G1
Cinli, TA1
Pehlivan, M1
Kürzel, S1
Blaudszun, AR1
Stahl, L1
Herbst, R1
Kroschinsky, F2
Birkmann, J2
Hänel, A1
Schaefer-Eckart, K1
Ehninger, G2
Fiedler, F1
Bornhäuser, M2
Fricke, S1
Hänel, M2
Fridthjof, KS1
Kampmann, P1
Dünweber, A1
Gørløv, JS1
Nexø, C1
Friis, LS1
Nørskov, KH1
Welinder, PC1
Moser, C1
Kjeldsen, L1
Møller, T1
Noesslinger, T1
Panny, M1
Simanek, R1
Moestl, M1
Boehm, A1
Menschel, E1
Koller, E1
Keil, F1
Olivieri, J1
Mosna, F1
Pelosini, M1
Fama, A1
Rattotti, S1
Giannoccaro, M1
Carli, G1
Tisi, MC1
Ferrero, S1
Sgherza, N1
Mazzone, AM1
Marino, D1
Calimeri, T1
Loseto, G1
Saraceni, F1
Tomei, G1
Sica, S1
Perali, G1
Codeluppi, K1
Billio, A1
Olivieri, A2
Orciuolo, E1
Matera, R1
Stefani, PM1
Borghero, C1
Ghione, P1
Cascavilla, N1
Lanza, F1
Chiusolo, P1
Finotto, S1
Federici, I1
Gherlinzoni, F1
Centurioni, R1
Fanin, R1
Zaja, F1
Salhotra, A1
Mei, M1
Stiller, T1
Mokhtari, S1
Herrera, AF1
Chen, R1
Popplewell, L1
Zain, J1
Ali, H1
Sandhu, K1
Budde, E1
Nademanee, A1
Forman, SJ1
Nakamura, R1
Dos Santos, KB1
Costa, LJM1
Bettarello, G1
da Matta Abreu, M1
Mayrink, GTC1
Mota, MA1
Ribeiro, LC1
Pereira, J1
Hallack Neto, AE1
Scortechini, I1
Montanari, M1
Mancini, G1
Inglese, E1
Calandrelli, M1
Chiarucci, M1
Offidani, M1
Capelli, D1
Gini, G1
Poloni, A1
Mancini, S1
Raggetti, G1
Leoni, P1
Marzolini, MA1
Thomson, KJ1
Dorman, J1
D'Sa, S1
Martin, N1
Borchiellini, D1
Coso, D1
Gastaud, L1
Boscagli, A1
Saudes, L1
Re, D1
Gutnecht, J1
Garnier, G1
Petit, E1
Barriere, J1
Naman, H1
Rossignol, B1
Thyss, A1
Ford, PA1
Grant, SJ1
Mick, R1
Keck, G1
Sellner, L1
Boumendil, A1
Finel, H1
de Rosa, G1
Falzetti, F1
Scime, R2
Kobbe, G1
Delmer, A1
Sayer, H1
Amorim, S1
Finke, J3
Salles, G1
Yakoub-Agha, I1
Faber, E1
Nicolas-Virelizier, E1
Facchini, L1
Vallisa, D1
Zuffa, E1
Sureda, A4
Dreger, P2
Lasica, M1
Taylor, E1
Bhattacharyya, P1
Bennett, A1
Cooke, RE1
Stern, C1
Agresta, F1
Ayton, R1
Grigg, A1
Flowers, CR1
Costa, LJ1
Pasquini, MC1
Le-Rademacher, J1
Lill, M1
Shore, TB1
Vaughan, W1
Craig, M1
Freytes, CO2
Shea, TC1
Horwitz, ME1
Fay, JW1
Mineishi, S1
Rondelli, D1
Mason, J1
Braunschweig, I2
Ai, W1
Yeh, RF1
Rodriguez, TE1
Flinn, I1
Comeau, T1
Yeager, AM1
Pulsipher, MA1
Bence-Bruckler, I1
Laneuville, P1
Bierman, P1
Chen, AI1
Kato, K1
Wang, Y1
Xu, C1
Smith, AJ1
Waller, EK1
Kothari, J1
Foley, M1
Peggs, KS1
Mackenzie, S1
Thomson, K1
Morris, E1
Ardeshna, KM1
Virchis, AE1
Linch, DC4
Cashen, AF1
Fletcher, T1
Ceriotti, C1
Gao, F1
Ghobadi, A1
Vij, R1
Stockerl-Goldstein, K1
DiPersio, J1
Abboud, C1
Reid, RM1
Baran, A1
Friedberg, JW3
Phillips, GL4
Liesveld, JL3
Becker, MW2
Wedow, L1
Barr, PM1
Milner, LA2
Gilli, S1
Novak, U1
Taleghani, BM1
Baerlocher, GM1
Leibundgut, K1
Banz, Y1
Zander, T1
Betticher, D1
Egger, T1
Rauch, D1
Pabst, T1
Fair, C1
Shanley, R1
Rogosheske, J1
Lazaryan, A1
McClune, B1
Brunstein, CG1
Bachanova, V1
Bruce, WR1
Valeriote, FA1
Meeker, BE1
Hunter, A1
Mahendra, P2
Wilson, K1
Fields, P1
Cook, G1
Crawley, C1
Hickling, R1
Marcus, R1
Rzepecki, P1
Pielichowski, W1
Oborska, S1
Barzal, J1
Mlot, B1
Bernstein, SH2
Abboud, CN2
Constine, LS1
Ifthikharuddin, JJ2
Loughner, JE1
Vesole, DH2
Lupov, IP1
Voiles, L1
Han, L1
Schwartz, A1
De La Rosa, M1
Oza, K1
Pelloso, D1
Sahu, RP1
Travers, JB1
Robertson, MJ1
Chang, HC1
Lane, AA1
Armand, P1
Feng, Y1
Neuberg, DS1
Abramson, JS1
Brown, JR1
Fisher, DC1
LaCasce, AS1
Jacobsen, ED1
McAfee, SL1
Spitzer, TR1
Freedman, AS1
Chen, YB1
Till, BG1
Madtes, DK1
Kasenda, B1
Schorb, E1
Fritsch, K1
Illerhaus, G2
O'Meara, A1
Halter, J2
Heim, D2
Gerull, S1
Bucher, C2
Passweg, J1
Buser, A1
Stern, M2
Shibamoto, Y1
Tomita, N1
Kono, T1
Tsuji, H1
Nankoh, S1
Taniguchi, H1
Au, WY1
Lie, AK1
Siu, LL1
Chan, EC1
Ooi, GC1
Leung, AY1
Liang, R1
Kwong, YL1
Poortmans, PM1
Kluin-Nelemans, HC1
Haaxma-Reiche, H1
Van't Veer, M1
Hansen, M1
Soubeyran, P1
Taphoorn, M1
Thomas, J1
Van den Bent, M1
Fickers, M1
Van Imhoff, G1
Rozewicz, C1
Teodorovic, I1
van Glabbeke, M1
Wang, EH1
Chen, YA1
Corringham, S1
Bashey, A1
Holman, P1
Ball, ED1
Carrier, E1
Martín, A2
Caballero, MD2
Pérez-Simón, JA2
López-Holgado, N2
Mateos, MV1
Cañizo, MC1
Miguel, JF1
Decaudin, D1
Vantelon, JM1
Bourhis, JH1
Farace, F1
Bonnet, ML1
Guillier, M1
Greissenger, N1
Marracho, MC1
Assari, S1
Bennaceur, AL1
Némati, F1
Michon, J1
Turhan, AG1
Boccaccio, C1
Korfel, A1
Martus, P1
Nowrousian, MR1
Hossfeld, DK1
Kirchen, H1
Brücher, J1
Stelljes, M1
Peschel, C1
Pasold, R1
Fischer, L1
Jahnke, K1
Thiel, E2
Vázquez, L1
del Cañizo, MC1
San Miguel, JF1
Lancet, JE1
Spreng, E1
Johnson, V1
Chapman, M1
Steele, TA3
Hauser, CC1
Brevet, M1
Garidi, R1
Gruson, B1
Royer, B1
Vaida, I1
Marks, R1
Ihorst, G1
Guttenberger, R1
Ostertag, C1
Derigs, G1
Frickhofen, N1
Feuerhake, F1
Volk, B1
Hölig, K1
Platzbecker, U1
Poppe-Thiede, K1
Ordemann, R1
Blechschmidt, M1
Oelschlaegel, U1
Schaich, M1
Colombat, P1
Lemevel, A1
Bertrand, P1
Rachieru, P1
Brion, A1
Berthou, C1
Bay, JO1
Delepine, R1
Desablens, B1
Camilleri-Broët, S1
Linassier, C1
Lamy, T1
Buser, AS1
Arber, C1
Meyer-Monard, S1
Stussi, G1
Lohri, A1
Ghielmini, M1
Tichelli, A1
Passweg, JR1
Gratwohl, A1
Horgan, CM1
Tisdale, MJ1
Portlock, CS1
Maruyama, Y8
Feola, JM4
Muir, W1
Oken, MM1
Costello, WG1
Johnson, GJ2
Lenhard, RE4
Ezdinli, EZ4
Orlow, E1
Barnes, JM2
Berard, CW2
Glick, JH3
Tannir, NM1
Spitzer, G1
Zander, AR2
Jagannath, S2
Kanojia, M1
Vellekoop, L1
McLaughlin, P2
Hagemeister, FJ1
Dicke, KA1
Philip, T1
Biron, P1
Hervé, P1
Dutou, L1
Ehrsam, A1
Philip, I1
Souillet, G1
Plouvier, E1
Le Mevel, A1
Philippe, N1
Marconi, P4
Scaringi, L1
Tissi, L3
Puccetti, P3
Cassone, A3
Hartmann, O1
Pein, F1
Beaujean, F2
Kalifa, C1
Patte, C1
Parmentier, C1
Lemerle, J1
Williams, AC1
Guadagni, F1
Roselli, M1
Fuggetta, MP1
Perno, CF1
Goldin, A5
Giuliani, A2
Case, DC1
Sklar, CA1
Kim, TH1
Ramsay, NK1
Weiss, RB1
Issell, BF1
Orlow, EL1
Bennett, JM4
Bistoni, F3
Cenci, E2
Pesce, CD1
Biegel, JA3
Boggs, SS3
Conner, MK2
Williams, A1
Nava, C1
Gibson, NW1
Hickman, JA1
Gomez, GA1
Aggarwal, KK1
Han, T1
Schwartz, GN1
Delfina Pesce, C1
Boccanera, M1
Feola, J2
Nathan, CF1
Cohn, ZA1
Bartocci, A1
Spreafico, F2
Bonmassar, E3
Stahel, RA1
Jost, LM1
Cerny, T1
Pichert, G1
Honegger, H1
Tobler, A1
Jacky, E1
Fey, M1
Platzer, E1
Fuchsberger, P1
Lakota, J1
Castenskiold, EC1
Kelsey, SM1
Collins, PW1
Coldwell, RD1
Allen, PD1
Side, LE1
Makin, HL1
Goldstone, AH5
Newland, AC1
Marquardt, P1
Haferlach, T1
Jacobs, S1
Mülverstedt, T1
Eckstein, V1
Suttorp, M1
Löffler, H1
Müller-Ruchholtz, W1
Schmitz, N2
Klingemann, HG1
Shepherd, JD1
Reece, DE1
Barnett, MJ1
Nantel, SH1
Sutherland, HJ1
Spinelli, JJ1
Kalaycioglu, M1
Kavuru, M1
Tuason, L1
Bolwell, B2
Snyder, MJ1
Johnson, DB1
Daly, MB1
Giguere, JK1
Harman, GH1
Harden, EA1
Johnson, RA1
Leff, RS1
Mercier, RJ1
Messerschmidt, GL1
Demirer, T1
Weaver, CH2
Buckner, CD2
Petersen, FB2
Bensinger, WI1
Sanders, J1
Clift, RA1
Lilleby, K1
Anasetti, C2
Martin, P2
Adkins, DR1
Salzman, D1
Boldt, D1
Kuhn, J1
Irvin, R1
Roodman, GD1
Lyons, R1
Smith, L1
LeMaistre, CF1
Barbot, C1
Rice, A1
Vanès, I1
Mahon, FX1
Jazwiec, B1
Reiffers, J1
Chatterjee, R1
Mills, W2
Katz, M1
McGarrigle, HH1
Attal, M1
Canal, P1
Schlaifer, D1
Chatelut, E1
Dezeuze, A1
Huguet, F1
Payen, C1
Pris, J1
Laurent, G1
Appelbaum, FR2
Clift, R1
Singer, J1
Press, O1
Bensinger, W1
Bianco, J1
Crilley, P2
Lazarus, H1
Topolsky, D2
Ciobanu, N2
Creger, RJ2
Fox, RM2
Bulova, SI2
Shina, DC2
Gucalp, R2
Cooper, BW2
Patti, C1
Majolino, I1
Indovina, A1
Vasta, S1
Liberti, G1
Gentile, S1
Santoro, A1
Pisa, R1
Caronia, F1
Carlson, K1
Smedmyr, B1
Hagberg, H1
Oberg, G1
Simonsson, B1
Smith, RJ1
Sweetenham, JW2
Strang, J1
Cox, DC2
Rosenfeld, CS1
LeFever, A1
Taylor, R1
List, A1
Fay, J1
Collins, R1
Andrews, F1
Pallansch, P1
Schuster, MW1
Resta, D1
Levitt, D1
Nemunaitis, J1
Ager, S1
Richards, EM1
Bass, G1
Baglin, TP1
Marcus, RE1
Ossenkoppele, GJ2
Schuurhuis, GJ1
Jonkhoff, AR1
Dräger, AM1
Westra, G1
Oberink, JW1
Legdeur, MC1
de Kreuk, AM1
Zweegman, S1
Huijgens, PC2
Fielding, AK1
Sullivan, AM1
Watts, MJ1
Jamieson, E1
Knauf, WU1
Koenigsmann, MP1
Notter, M1
Hoppe, B1
Reufi, B1
Oberberg, D1
Berdel, WE1
Diehl, V2
Martínez, C2
Martino, R3
Cancelas, JA1
Madoz, P2
García, J1
Brunet, S3
Kröger, N1
Zeller, W1
Fehse, N1
Hassan, HT1
Krüger, W1
Gutensohn, K1
Lölliger, C1
Przepiorka, D1
van Besien, K1
Khouri, I1
Hagemeister, F1
Samuels, B1
Folloder, J1
Ueno, NT1
Molldrem, J1
Mehra, R1
Körbling, M2
Giralt, S1
Gajewski, J1
Donato, M1
Cleary, K1
Claxton, D1
Andersson, B1
Anderlini, P1
Champlin, R1
Muñoz, L2
Subirà, M1
Sierra, J2
Josting, A1
Reiser, M1
Wickramanayake, PD1
Rueffer, U1
Draube, A1
Söhngen, D1
Tesch, H1
Wolf, J1
Engert, A1
Cull, GM1
Haynes, AP1
Byrne, JL1
Carter, GI1
Miflin, G1
Rebello, P1
Hale, G1
Waldmann, H1
Russell, NH1
George, P1
Wyre, RM1
Bruty, SJ1
Duncombe, AS1
Altés, A1
López, R1
Cabezudo, E1
Santamaría, A1
Perea, G1
Briones, J1
Salar, A1
Slabý, J1
Trnený, M1
Procházka, B1
Klener, P1
Bessell, EM1
López-Guillermo, A1
Villá, S1
Verger, E1
Nomdedeu, B1
Petit, J1
Byrne, P1
Montserrat, E1
Graus, F1
Becherer, A1
Mitterbauer, M1
Jaeger, U1
Kalhs, P1
Greinix, HT1
Karanikas, G1
Pötzi, C1
Raderer, M1
Dudczak, R1
Kletter, K1
Bakemeier, RF1
Carbone, PP2
Ezdinli, E2
Pocock, SJ2
Durant, JR4
Gams, RA2
Bartolucci, AA3
Dorfman, RF1
Costello, W1
Horton, J1
Amorisi, EL1
Stolbach, L1
Wolter, J1
Pitzurra, M1
Frati, L1
Drewinko, B2
Loo, TL2
Freireich, EJ1
Norgard, MJ1
Murad, TM1
Langford, KH1
Bonmassar, A1
Smith, RH1
Muren, O1
Scott, RB1
Frable, WJ1
Costanzi, JJ1
Raju, MR1
Bains, E1
Jett, J1
Simon, R1
Wasserman, TH1
Slavik, M1
Carter, SK2
Loeb, V1
Dorfman, R1
Chan, YK1
Houchens, DP1
Fioretti, MC2
Wollner, N2
Burchenal, JH2
Lieberman, PH2
Exelby, PR1
D'Angio, GJ1
Murphy, ML2
Exelby, P1
D'Angio, G1
Gottlieb, JA1
Lazarus, HM1
Smith, AG1
Long, SG1
Janmohammed, RM1
Macdonald, DF1
Leyland, MJ1
Milligan, DW1
Selvan, RS2
Nagarkatti, PS3
Nagarkatti, M4
Turriziani, M1
Bulgarini, B1
De Vecchis, L1
Ayash, LJ1
Hunt, M1
Antman, K1
Nadler, L1
Wheeler, C1
Takvorian, T1
Elias, A1
Antin, JH1
Greenough, T1
Eder, JP1
Sensi, M1
Bergomi, M1
Formelli, F1
Parmiani, G1
Boros, L1
Peng, YM1
Alberts, DS1
Asbury, RF1
Goodman, TL1
Penn, TE1
Hickox, DE1
Ito, H1
Rousseau, V1
Goavec, M1
Morizet, J1
Stanislawski, M1
Zackheim, HS1
Epstein, EH1
Crain, WR1
Gingrich, RD1
Ginder, GD1
Burns, LJ1
Wen, BC1
Fyfe, MA1
Fuschiotti, P1
Dominici, P1
Borri-Voltattorni, C1
Romani, L1
Keilholz, U1
Fehrentz, D1
Bauer, H1
Hunstein, W1
Kryscio, R1
Cabanillas, F1
Velasquez, WS1
Hagemeister, FB1
Redman, JR1
Swan, F1
Rodriguez, MA1
Gaspard, MH1
Maraninchi, D1
Stoppa, AM1
Gastaut, JA1
Michel, G1
Tubiana, N1
Blaise, D1
Novakovitch, G1
Rossi, JF1
Weiller, PJ1
Malkin, MG1
Shapiro, WR1
Kaplan, AM2
van der Lelie, J1
Thomas, LL1
Wijngaarden, MJ1
Reijneke, RM1
Anderson, CC1
Souhami, RL1
Harper, PG1
McLennan, KA1
Jones, M1
Machin, SJ1
Jelliffe, AM1
Cawley, JC1
Anderson, JR1
Melvin, F1
Davis, TE1
O'Connell, MJ1
Sullivan, MP1
Boyett, J1
Pullen, J1
Crist, W1
Doering, EJ1
Trueworthy, R1
Hvizdala, E1
Ruymann, F1
Steuber, CP1
Rainey, M1
Dandy, M1
Silberman, H1
Omura, G1
Vonderheid, EC1
Micaily, B1
Cohen, IJ1
Vogel, R1
Matz, S1
Weitz, R1
Mor, C1
Stern, S1
Zaizov, R1
Schabel, FM2
Skipper, HE1
Trader, MW1
Laster, WR1
Cheeks, JB1
Frei, E1
De Vita, VT1
Canellos, GP1
Schein, PJ1
Chabner, BA1
Bagley, CM1
Young, RC1
Aungst, CW1
Lessner, HE1
Fairley, GH1

Clinical Trials (23)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841]Phase 3250 participants (Anticipated)Interventional2014-07-31Recruiting
Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)[NCT00003061]Phase 250 participants (Anticipated)Interventional1997-07-31Completed
Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation[NCT00647049]Phase 278 participants (Anticipated)Interventional2007-01-31Recruiting
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]Phase 211 participants (Actual)Interventional2010-10-14Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
A Phase II, Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655]Phase 251 participants (Anticipated)Interventional2020-09-01Not yet recruiting
Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287]Phase 3429 participants (Actual)Interventional2017-09-23Completed
Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease[NCT00287248]Phase 138 participants (Actual)Interventional2006-02-28Completed
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Data Collection and Analysis of COVID-19 Patients Treated With ClorNovir® (Chlorpheniramine Maleate (0.4% Nasal Spray)[NCT05520944]1,000 participants (Anticipated)Observational2021-08-26Active, not recruiting
Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors[NCT05349227]660 participants (Anticipated)Interventional2022-06-23Recruiting
Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028]100 participants (Anticipated)Observational2021-03-10Not yet recruiting
Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders[NCT03415672]Phase 2133 participants (Actual)Interventional2017-10-11Completed
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis[NCT00001646]Phase 310 participants Interventional1997-08-31Completed
Building Strength Through Rehabilitation for Heart Failure Patients[NCT03615469]15 participants (Actual)Interventional2018-09-06Terminated (stopped due to Low recruitment numbers)
Impact of Treatment of Mild Sleep-Disordered Breathing on Children's Health[NCT02562040]459 participants (Actual)Interventional2016-06-01Completed
EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.[NCT05025787]Phase 277 participants (Anticipated)Interventional2021-10-25Recruiting
A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor[NCT01652469]Phase 381 participants (Actual)Interventional2012-08-31Completed
Healthy Weight and Stress Management Study[NCT05279989]25 participants (Actual)Interventional2021-12-01Completed
Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures[NCT01526265]2,185 participants (Anticipated)Interventional2012-02-29Completed
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109]Phase 2188 participants (Anticipated)Interventional2020-10-21Recruiting
Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586]Phase 3374 participants (Anticipated)Interventional2012-03-31Recruiting
Comparison of Surgical Wound Healing and Complications Following Revision Hip and Knee Replacements, Utilising a 7-day Versus 14-day Negative Pressure Wound Therapy (NPWT) Dressing. A Randomised Controlled Trial.[NCT05389410]100 participants (Anticipated)Interventional2022-09-30Not yet recruiting
OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC[NCT03827577]Phase 3195 participants (Anticipated)Interventional2019-10-01Recruiting
Phase II Study of Intensive Carmustine and Etoposide With Cisplatin or Cyclophosphamide, Followed By Rescue With Autologous Bone Marrow Treated In Vitro With Etoposide and/or Peripheral Blood Stem Cells Mobilized With Filgrastim (G-CSF) or Sargramostim (G[NCT00002461]Phase 235 participants (Actual)Interventional1988-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Safest Dose of Temozolomide for the DRBEAT Regimen

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

Interventiondose in mg/m^2 (Number)
DRBEAT Regimen773.25

One-year Progression-free Survival and Overall Survival

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

InterventionDays (Median)
Progression Free SurvivalOverall Survival
DRBEAT Regimen132564

Change in 6 Minute Walk Test

The 6-min walk test (6MWT) estimates the person's ability to perform everyday activities by measuring the distance walked in a set time period. It will be used to measure exercise capacity, specific aim 2. Participants will be allowed use of an assistive device and will be instructed to move as quickly as they feel safe and comfortable over the 100-meter course for 6 minutes. As per the protocol, participants will be allowed to stop and rest if necessary. This test is recommended by the American Thoracic Society for patients with moderate to severe heart or lung disease. (NCT03615469)
Timeframe: From Baseline to 5-6 months

Interventionmeters walked (Mean)
Neuromusclar Electrical Stimulation324
Transcutaneous Electrical Stimulation250.6

Overall Survival

Defined as time from the date of randomization until death from any cause. (NCT01652469)
Timeframe: All patients will be followed for survival status every 12 weeks up to 24 months after the last patient is randomized

Interventionmonths (Median)
A: Erlotinib7.1
B: Docetaxel7.1

Progression-free Survival

"Time from the date of randomization until documented progression or death without documented progression.~Assessment of Progressive Disease (PD) based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) Target lesions:At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.(Note: the appearance of one or more new lesions is also considered progression).~Non-target lesions:Unequivocal progression of existing non-target lesions. (Note:the appearance of one or more new lesions is also considered progression). To achieve 'unequivocal progression', there must be an overall level of substantial worsening in non-target disease such that,even in presence of SD or PR in target disease, the overall tumour burden has increased sufficiently" (NCT01652469)
Timeframe: The combined run in period, treatment and follow-up for PFS is expected to extend the study duration to a total of 24 months.

Interventionmonths (Median)
A: Erlotinib1.6
B: Docetaxel3.0

Number of Participants With Adverse Events

Adverse events classified according to NCI CTCAE version 4 (NCT01652469)
Timeframe: Same as primary outcome: 24 months

,
InterventionParticipants (Count of Participants)
Experienced AE/SAENo AE/SAEExperienced SAE
A: Erlotinib3627
B: Docetaxel39219

Reviews

11 reviews available for carmustine and Lymphoma

ArticleYear
[Evidence-based radiation therapy for primary brain tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Evidence-Based Medicine; Glioma; Hum

2003
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
    Cancer treatment reviews, 1982, Volume: 9, Issue:4

    Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod

1982
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
    Bone marrow transplantation, 1994, Volume: 14 Suppl 4

    Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr

1994
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
    Cancer treatment reports, 1977, Volume: 61, Issue:6

    Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad

1977
Clinical comparison of the nitrosoureas.
    Cancer, 1975, Volume: 36, Issue:4

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C

1975
Brain tumors.
    Cancer chemotherapy and biological response modifiers, 1987, Volume: 9

    Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Glioma; Humans; Infusions, Intra-Arterial

1987
Overview of the clinical relevance of autologous bone marrow transplantation.
    Clinics in haematology, 1986, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla

1986
Treatment of cutaneous T-cell lymphoma.
    Dermatologic clinics, 1985, Volume: 3, Issue:4

    Topics: Adjuvants, Immunologic; Administration, Topical; Carmustine; Combined Modality Therapy; Humans; Immu

1985
An overview of the status of the nitrosoureas in other tumors.
    Cancer chemotherapy reports. Part 3, 1973, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br

1973
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
    Proceedings. National Cancer Conference, 1972, Volume: 7

    Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru

1972
Combination chemotherapy in malignant diseases.
    Journal of the Royal College of Physicians of London, 1971, Volume: 5, Issue:2

    Topics: Adult; Antineoplastic Agents; Asparaginase; Carmustine; Child; Cyclophosphamide; Cytarabine; Cytosin

1971

Trials

45 trials available for carmustine and Lymphoma

ArticleYear
Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Fr

2020
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos

2022
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabin

2019
LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma.
    Bone marrow transplantation, 2019, Volume: 54, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Et

2019
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7

    Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hemat

2016
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:12

    Topics: Adolescent; Adult; Aged; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic St

2016
BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
    Bone marrow transplantation, 2017, Volume: 52, Issue:3

    Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fem

2017
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.
    Bone marrow transplantation, 2009, Volume: 43, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dou

2009
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmus

2011
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival

2013
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-15, Volume: 21, Issue:24

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous

2003
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
    Bone marrow transplantation, 2004, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies;

2004
Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.
    Bone marrow transplantation, 2004, Volume: 34, Issue:12

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Culture Techniques;

2004
Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
    British journal of haematology, 2005, Volume: 128, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop

2005
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18

    Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The

2004
First-line autologous stem cell transplantation in primary CNS lymphoma.
    European journal of haematology, 2005, Volume: 75, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop

2005
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Transfusion, 2006, Volume: 46, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone;

2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Bone marrow transplantation, 2006, Volume: 38, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Bone marrow transplantation, 2006, Volume: 38, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Bone marrow transplantation, 2006, Volume: 38, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Bone marrow transplantation, 2006, Volume: 38, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
    Bone marrow transplantation, 2007, Volume: 39, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs

2007
Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy.
    Blood, 1981, Volume: 58, Issue:5

    Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Dru

1981
Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma.
    Cancer, 1982, Dec-01, Volume: 50, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug

1982
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1994
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1995
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali

1994
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta

1994
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma.
    Leukemia & lymphoma, 1995, Volume: 17, Issue:3-4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1995
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
    Bone marrow transplantation, 1996, Volume: 17, Issue:2

    Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Admi

1996
Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
    Leukemia & lymphoma, 1996, Volume: 23, Issue:3-4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine;

1996
Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
    Bone marrow transplantation, 1997, Volume: 20, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The

1997
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:1-2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos

2000
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Neoplasma, 2000, Volume: 47, Issue:5

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th

2000
Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-01, Volume: 20, Issue:1

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central

2002
Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group.
    Cancer treatment reports, 1976, Volume: 60, Issue:6

    Topics: Bleomycin; Carmustine; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug T

1976
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
    Cancer treatment reports, 1977, Volume: 61, Issue:6

    Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad

1977
BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
    Cancer treatment reports, 1977, Volume: 61, Issue:6

    Topics: Carmustine; Cell Cycle; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Therapy, Combin

1977
Treatment of histiocytic and mixed lymphomas: a comparison of two, three and four drug chemotherapy.
    Cancer, 1978, Volume: 42, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Drug Evaluation; Drug

1978
DTIC (NSC-45388) studies in the southwest oncology group.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co

1976
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Biometrics, 1975, Volume: 31, Issue:1

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom

1975
High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow

1992
BEAM autografting in lymphoma--experience at one centre.
    Leukemia & lymphoma, 1992, Volume: 7 Suppl

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1992
Overview of the clinical relevance of autologous bone marrow transplantation.
    Clinics in haematology, 1986, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla

1986
Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Follow-Up Stud

1985
Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).
    Cancer, 1985, Jan-15, Volume: 55, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow; Carmustine; Child; Child, Preschool; C

1985
Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials

1985

Other Studies

115 other studies available for carmustine and Lymphoma

ArticleYear
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone marrow transplantation, 2022, Volume: 57, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra

2022
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
    Transplantation and cellular therapy, 2023, Volume: 29, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine;

2023
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Transplantation and cellular therapy, 2023, Volume: 29, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste

2023
The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.
    Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2023, Volume: 36, Issue:5

    Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Human

2023
Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients.
    International journal of hematology, 2020, Volume: 111, Issue:6

    Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, P

2020
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste

2020
Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
    Bone marrow transplantation, 2021, Volume: 56, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Humans; Lomustine

2021
Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study.
    Hematology/oncology and stem cell therapy, 2021, Volume: 14, Issue:4

    Topics: Bendamustine Hydrochloride; Cardiotoxicity; Carmustine; Hematopoietic Stem Cell Transplantation; Hum

2021
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
    Hematology/oncology and stem cell therapy, 2022, Dec-23, Volume: 15, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste

2022
Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
    British journal of haematology, 2018, Volume: 181, Issue:5

    Topics: Acute Disease; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmust

2018
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
    European journal of haematology, 2018, Volume: 101, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine;

2018
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; F

2018
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:7

    Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hemat

2014
BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.
    Bone marrow transplantation, 2014, Volume: 49, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hu

2014
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cy

2015
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-20, Volume: 33, Issue:15

    Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; C

2015
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
    Bone marrow transplantation, 2016, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cyt

2016
Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning.
    European journal of haematology, 2016, Volume: 97, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; F

2016
A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
    Bone marrow transplantation, 2016, Volume: 51, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoi

2016
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
    Cancer medicine, 2016, Volume: 5, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali

2016
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.
    Annals of hematology, 2017, Volume: 96, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Carmustine;

2017
Survival of mice bearing a transplanted syngeneic lymphoma following treatment with cyclophosphamide, 5-fluorouracil, or 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Journal of the National Cancer Institute, 1967, Volume: 39, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Fluor

1967
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
    Transplantation proceedings, 2009, Volume: 41, Issue:8

    Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma

2009
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
    Blood, 2011, Dec-01, Volume: 118, Issue:23

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic

2011
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy;

2012
BCNU-associated pneumonitis: portrait of a toxicity.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Etoposide; Female; Hum

2012
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop

2012
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
    Annals of hematology, 2003, Volume: 82, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Gr

2003
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Bone marrow transplantation, 2004, Volume: 34, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas

2004
Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
    Haematologica, 2005, Volume: 90, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Bo

2005
The role of interferon-alpha in a successful murine tumor therapy.
    Experimental biology and medicine (Maywood, N.J.), 2005, Volume: 230, Issue:7

    Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Prolifera

2005
Antitumour imidazotetrazines--IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451).
    Biochemical pharmacology, 1984, Jul-15, Volume: 33, Issue:14

    Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carmus

1984
Management of the indolent non-Hodgkin's lymphomas.
    Seminars in oncology, 1980, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati

1980
1,3-bis(2-chloroethyl)-1-nitrosourea treatment of spontaneous radiogenic C57BL mouse leukemia/lymphoma.
    Gan, 1983, Volume: 74, Issue:3

    Topics: Animals; Carmustine; Leukemia Virus, Murine; Leukemia, Radiation-Induced; Lymphoma; Lymphoma, Non-Ho

1983
The influence of histologic subtype on toxicity and response to chemotherapy in non-hodgkin's lymphoma. An Eastern Cooperative Oncology Group Study utilizing the BCVP regimen.
    Cancer, 1983, May-01, Volume: 51, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide;

1983
High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma.
    European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:8

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1983
Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of non-Hodgkin's malignant lymphoma with a very bad prognosis.
    European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1983
Combined effects of chemotherapy and host antitumor response in a murine histocompatible lymphoma model.
    International journal of immunopharmacology, 1984, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents; Candida albicans; Carmustine; Combined Modality Therapy; Fungal Vacc

1984
High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:9

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine;

1984
Adoptive transfer of immunity by spleen cells from LSA-lymphoma mice cured by BCNU.
    Leukemia research, 1984, Volume: 8, Issue:4

    Topics: Animals; Bone Marrow; Carmustine; Immunization, Passive; Lymphoma; Mice; Mice, Inbred C57BL; Spleen;

1984
Increased immunogenicity of murine lymphoma cells following exposure to gamma rays in vivo.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1984, Volume: 3, Issue:6

    Topics: Animals; Carmustine; Dacarbazine; Gamma Rays; Histocompatibility Antigens; Immune Tolerance; Immunit

1984
Comparison of M-2 protocol with COP in patients with nodular lymphoma.
    Oncology, 1984, Volume: 41, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cyclophos

1984
Thyroid dysfunction among long-term survivors of bone marrow transplantation.
    The American journal of medicine, 1982, Volume: 73, Issue:5

    Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Carmustine; Child; Child, Preschoo

1982
Immunopotentiation of anticancer chemotherapy by Candida albicans, other yeasts and insoluble glucan in an experimental lymphoma model.
    Sabouraudia, 1982, Volume: 20, Issue:2

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Candida albicans; Carmustine; Cell Wall; Cry

1982
In vivo sister chromatid exchange and cellular replication kinetics of normal and lymphoma AKR bone marrow cells.
    Cancer research, 1982, Volume: 42, Issue:7

    Topics: Animals; Bone Marrow; Bone Marrow Cells; Carmustine; Cell Cycle; Cell Line; Crossing Over, Genetic;

1982
Cellular replication kinetics and persistence of sister chromatid exchange-inducing lesions in normal and lymphoma AKR cells following exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Cancer research, 1982, Volume: 42, Issue:7

    Topics: Animals; Bone Marrow; Bromodeoxyuridine; Carmustine; Cell Cycle; Cell Division; Cell Line; Crossing

1982
Evidence for host resistance in 1,3 bis(2-chloroethyl)-1-nitrosourea treatment induced in syngeneic LSA lymphoma.
    Journal of cancer research and clinical oncology, 1982, Volume: 103, Issue:2

    Topics: Animals; Carmustine; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Female; Immunity, I

1982
The role of isocyanates in the toxicity of antitumour haloalkylnitrosoureas.
    Biochemical pharmacology, 1982, Sep-01, Volume: 31, Issue:17

    Topics: Animals; Antineoplastic Agents; Carmustine; Cyanates; Female; Leukemia L1210; Lomustine; Lymphoma; M

1982
A model to study drug effects on lymphoma and normal cell populations using the AKR/J mouse.
    Leukemia research, 1982, Volume: 6, Issue:2

    Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Germanium; Karyotyping; Leukemia, Experiment

1982
[Further study of immunopotentiation in experimental antiblastic therapy by inactivated yeasts and glucan].
    Annali dell'Istituto superiore di sanita, 1982, Volume: 18, Issue:3

    Topics: Adjuvants, Immunologic; Animals; Carmustine; Combined Modality Therapy; Female; Fluorouracil; Glucan

1982
1,3 Bis (2-chloroethyl)-1-nitrosourea-induced host resistance to syngeneic LSA mouse leukemia.
    Leukemia research, 1980, Volume: 4, Issue:5

    Topics: Animals; Carmustine; Hematopoietic Stem Cells; Immunity; Leukemia, Experimental; Lymphoma; Mice; Neo

1980
Antitumor effects of hydrogen peroxide in vivo.
    The Journal of experimental medicine, 1981, Nov-01, Volume: 154, Issue:5

    Topics: Animals; Antineoplastic Agents; Carmustine; Drug Synergism; Female; Glucose Oxidase; Hydrogen Peroxi

1981
Combined effects of antineoplastic agents and anti-lymphoma allograft reactions.
    European journal of cancer, 1980, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dacarbazine; Female; Histocompatibilit

1980
High-dose chemotherapy and autologous peripheral stem cell transplantation in patients with relapsing malignant lymphomas--first experience in the Slovak Republic.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carmustine; Cyclo

1995
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
    Bone marrow transplantation, 1995, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marr

1995
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
    British journal of cancer, 1993, Volume: 68, Issue:5

    Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tra

1993
Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).
    Chest, 1995, Volume: 107, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Forced Expirato

1995
Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Bone marrow transplantation, 1994, Volume: 14, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb

1994
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
    Nouvelle revue francaise d'hematologie, 1994, Volume: 36, Issue:4

    Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosph

1994
Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
    Bone marrow transplantation, 1994, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1994
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1993
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
    Seminars in oncology, 1993, Volume: 20, Issue:4 Suppl 4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu

1993
High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
    European journal of haematology, 1993, Volume: 51, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colo

1993
Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.
    Bone marrow transplantation, 1993, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1993
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Experimental hematology, 1995, Volume: 23, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide;

1995
Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine.
    Cancer biotherapy, 1995,Winter, Volume: 10, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Cyclosporine; Imm

1995
Elimination of EL-4 and L1210 murine tumors by 1,3-bis (2-chloroethyl)-1-nitrosourea requires an intact immune response.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1996, Volume: 212, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cyclosporine; Immunosuppressive Agents; Leuk

1996
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
    Bone marrow transplantation, 1996, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali

1996
G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma.
    Bone marrow transplantation, 1996, Volume: 18, Issue:2

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cold Temperature;

1996
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.
    Bone marrow transplantation, 1996, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide

1996
Carmustine and the lungs .
    Lancet (London, England), 1997, Jun-14, Volume: 349, Issue:9067

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Female; Hodgkin Disease; Huma

1997
Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
    British journal of haematology, 1998, Volume: 102, Issue:4

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colon

1998
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Graft vs Host

1999
Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma.
    Leukemia & lymphoma, 1999, Volume: 34, Issue:5-6

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bact

1999
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
    British journal of haematology, 2000, Volume: 108, Issue:4

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm;

2000
Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma.
    Journal of hematotherapy & stem cell research, 2000, Volume: 9, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Automation; Biomarkers

2000
Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
    Bone marrow transplantation, 2000, Volume: 26, Issue:2

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Count;

2000
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Leukemia, 2002, Volume: 16, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop

2002
Action of radiation or alkylating agents on LSA lymphoma during growth.
    International journal of radiation oncology, biology, physics, 1979, Volume: 5, Issue:2

    Topics: Alkylating Agents; Animals; Carmustine; Cell Survival; Cobalt Radioisotopes; Cyclophosphamide; Dose-

1979
Host resistance to tumor after cure of advanced LSA lymphoma by treatment with BCNU and chlorozotocin.
    Cancer treatment reports, 1979, Volume: 63, Issue:8

    Topics: Animals; Carmustine; Drug Therapy, Combination; Lymphoma; Male; Mice; Neoplasms, Experimental; Strep

1979
Combined effects of BCG or Candida albicans (CA) with antitumor agents against a virus-induced lymphoma in mice.
    European journal of cancer, 1979, Volume: 15, Issue:11

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; BCG Vaccine; Candida albicans; Carmustine; D

1979
Combination chemotherapy in vitro. III. BCNU.
    Cancer treatment reports, 1979, Volume: 63, Issue:3

    Topics: Antineoplastic Agents; Carmustine; Cell Survival; Drug Synergism; Humans; In Vitro Techniques; Lymph

1979
Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU).
    Annals of internal medicine, 1979, Volume: 90, Issue:2

    Topics: Adolescent; Adult; Aged; Carmustine; Cough; Dyspnea; Female; Humans; Hypoxia; Lymphoma; Male; Middle

1979
Influence of presensitization with allogeneic lymphoma cells on the growth and response to therapy of radiation-induced lymphomas in mice.
    Experientia, 1979, Aug-15, Volume: 35, Issue:8

    Topics: Animals; Carmustine; Female; Lymphoma; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental

1979
Transbronchial brush biopsy: anti-mortem diagnosis of pulmonary infiltrates in non-Hodgkin's lymphoma.
    Virginia medical, 1978, Volume: 105, Issue:5

    Topics: Adult; Aged; Bronchi; Bronchoscopy; Carmustine; Doxorubicin; Humans; Lung Neoplasms; Lymphoma; Male

1978
Carmustine (BiCNU).
    The Medical letter on drugs and therapeutics, 1978, Sep-08, Volume: 20, Issue:18

    Topics: Brain Neoplasms; Carmustine; Hodgkin Disease; Humans; Lymphoma; Multiple Myeloma

1978
Study of in vivo tumor state and response to therapy by analysis of DNA distribution.
    Cancer treatment reports, 1976, Volume: 60, Issue:5

    Topics: Animals; Carmustine; Cell Survival; Cobalt Radioisotopes; DNA, Neoplasm; Female; Hydroxyurea; Kineti

1976
1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
    Cancer, 1975, Volume: 36, Issue:6

    Topics: Carmustine; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Lar

1975
Uptake of 5-iododeoxyuridine as a measure of tumor growth and tumor inhibition.
    Chemotherapy, 1975, Volume: 21, Issue:6

    Topics: Animals; Carmustine; Cell Transformation, Neoplastic; Cyclophosphamide; DNA, Neoplasm; Female; Idoxu

1975
Non-Hodgkin's lymphoma in children.
    Medical and pediatric oncology, 1975, Volume: 1, Issue:3

    Topics: Adolescent; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cycloph

1975
Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.
    Cancer, 1976, Volume: 37, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Asparaginase; Carmustine; Child; Child, Preschool; Cyclophosphami

1976
A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells.
    Cancer research, 1976, Volume: 36, Issue:2 Pt 1

    Topics: Amphotericin B; Carmustine; Cell Line; Cell Survival; Cells, Cultured; Dose-Response Relationship, D

1976
Characterization of T lymphocyte clones isolated from BCNU-cured LSA mice.
    International journal of cell cloning, 1991, Volume: 9, Issue:6

    Topics: Animals; Carmustine; CD8 Antigens; Clone Cells; Cytotoxicity, Immunologic; Female; Interleukin-2; In

1991
Role of levamisole as immunomodulant in mouse lymphoma model.
    Immunopharmacology and immunotoxicology, 1991, Volume: 13, Issue:3

    Topics: Animals; Carmustine; Cytarabine; Dacarbazine; Drug Synergism; Female; Immune Tolerance; Levamisole;

1991
Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T cytotoxic cells.
    International journal of cancer, 1990, Jun-15, Volume: 45, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antigen-Presenting Cells; Antigens, Differentiation, T-Lymphocyte;

1990
Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:10

    Topics: Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Female; Hepatic Veno-Occl

1990
Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity.
    International journal of cancer, 1990, Dec-15, Volume: 46, Issue:6

    Topics: Animals; Carmustine; Cytotoxicity, Immunologic; Female; Killer Cells, Lymphokine-Activated; Lymphoma

1990
Pharmacokinetics of very high-dose oral melphalan in cancer patients.
    American journal of clinical oncology, 1990, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Biologi

1990
Enhanced in vitro cytotoxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea or buthionine sulfoximine combined with a reactive oxygen-generating enzyme immunotoxin.
    Cancer letters, 1990, Volume: 49, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Carmustine; Cell Survival; C

1990
Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients.
    Journal of the American Academy of Dermatology, 1990, Volume: 22, Issue:5 Pt 1

    Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carmustine; Drug Administration Schedule;

1990
BVAC ablative chemotherapy followed by autologous bone marrow transplantation for patients with advanced lymphoma.
    Blood, 1990, Jun-15, Volume: 75, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1990
DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives.
    International journal of cancer, 1987, Jun-15, Volume: 39, Issue:6

    Topics: Animals; Azacitidine; Carmustine; Cell Line; Cytarabine; Dacarbazine; DNA, Neoplasm; Lymphoma; Male;

1987
Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
    Cancer, 1989, Aug-01, Volume: 64, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb

1989
Treatment of primary radiogenic C57BL mouse cell leukemia/lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy and adjuvant cellular therapy.
    Japanese journal of cancer research : Gann, 1985, Volume: 76, Issue:12

    Topics: Animals; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Female; Immunotherapy;

1985
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
    Seminars in hematology, 1988, Volume: 25, Issue:2 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin;

1988
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
    Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1988
The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
    Journal of immunology (Baltimore, Md. : 1950), 1985, Volume: 135, Issue:2

    Topics: Animals; Carmustine; Cytotoxicity, Immunologic; Female; Graft Rejection; Immunity, Innate; Immunizat

1985
Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
    Cancer immunology, immunotherapy : CII, 1988, Volume: 27, Issue:1

    Topics: Animals; Carmustine; Cell Line; Cytotoxicity, Immunologic; Female; Immunity, Cellular; Killer Cells,

1988
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1988
Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl

1986
Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB).
    Cancer, 1986, Jan-01, Volume: 57, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Dexam

1986
Combination chemotherapy for spontaneous AKR lymphoma.
    Cancer chemotherapy reports. Part 2, 1974, Volume: 4, Issue:1

    Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara

1974
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Cancer research, 1974, Volume: 34, Issue:1

    Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara

1974
Treatment of Hodgkin's disease and other malignant lymphomas.
    Journal of surgical oncology, 1973, Volume: 5, Issue:6

    Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide;

1973
Development of four-drug BCNU combination chemotherapy regimens.
    Cancer, 1973, Volume: 32, Issue:2

    Topics: Carmustine; Cyclophosphamide; Evaluation Studies as Topic; Hematologic Diseases; Hodgkin Disease; Hu

1973